Literature DB >> 23076242

The ebolavirus VP24 interferon antagonist: know your enemy.

Adrianna P P Zhang1, Dafna M Abelson, Zachary A Bornholdt, Tong Liu, Virgil L Woods, Erica Ollmann Saphire.   

Abstract

Suppression during the early phases of the immune system often correlates directly with a fatal outcome for the host. The ebolaviruses, some of the most lethal viruses known, appear to cripple initial stages of the host defense network via multiple distinct paths. Two of the eight viral proteins are critical for immunosuppression. One of these proteins is VP35, which binds double-stranded RNA and antagonizes several antiviral signaling pathways. The other protein is VP24, which binds transporter molecules to prevent STAT1 translocation. A more recent discovery is that VP24 also binds STAT1 directly, suggesting that VP24 may operate in at least two separate branches of the interferon pathway. New crystal structures of VP24 derived from pathogenic and nonpathogenic ebolaviruses reveal its novel, pyramidal fold, upon which can be mapped sites required for virulence and for STAT1 binding. These structures of VP24, and new information about its direct binding to STAT1, provide avenues by which we may explore its many roles in the viral life cycle, and reasons for differences in pathogenesis among the ebolaviruses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23076242      PMCID: PMC3485981          DOI: 10.4161/viru.21302

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  37 in total

1.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

3.  Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription.

Authors:  T Hoenen; S Jung; A Herwig; A Groseth; S Becker
Journal:  Virology       Date:  2010-05-04       Impact factor: 3.616

4.  The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase.

Authors:  Peter Halfmann; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Cell type-specific and tyrosine phosphorylation-independent nuclear presence of STAT1 and STAT3.

Authors:  Thomas Meyer; Karsten Gavenis; Uwe Vinkemeier
Journal:  Exp Cell Res       Date:  2002-01-01       Impact factor: 3.905

6.  How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene.

Authors:  M Chatterjee-Kishore; K L Wright; J P Ting; G R Stark
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

7.  Molecular characterization of guinea pig-adapted variants of Ebola virus.

Authors:  V E Volchkov; A A Chepurnov; V A Volchkova; V A Ternovoj; H D Klenk
Journal:  Virology       Date:  2000-11-10       Impact factor: 3.616

8.  Marburg virus VP40 antagonizes interferon signaling in a species-specific manner.

Authors:  Charalampos Valmas; Christopher F Basler
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

9.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

10.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  14 in total

1.  Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1.

Authors:  Wei Xu; Megan R Edwards; Dominika M Borek; Alicia R Feagins; Anuradha Mittal; Joshua B Alinger; Kayla N Berry; Benjamin Yen; Jennifer Hamilton; Tom J Brett; Rohit V Pappu; Daisy W Leung; Christopher F Basler; Gaya K Amarasinghe
Journal:  Cell Host Microbe       Date:  2014-08-13       Impact factor: 21.023

2.  Analysis of the highly diverse gene borders in Ebola virus reveals a distinct mechanism of transcriptional regulation.

Authors:  Kristina Brauburger; Yannik Boehmann; Yoshimi Tsuda; Thomas Hoenen; Judith Olejnik; Michael Schümann; Hideki Ebihara; Elke Mühlberger
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

Review 3.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

Review 4.  A dead-end host: is there a way out? A position piece on the ebola virus outbreak by the international union of immunology societies.

Authors:  Clive M Gray; Marylyn Addo; Reinhold E Schmidt
Journal:  Front Immunol       Date:  2014-10-27       Impact factor: 7.561

5.  The PDB database is a rich source of alpha-helical anti-microbial peptides to combat disease causing pathogens.

Authors:  Sandeep Chakraborty; My Phu; Tâmara Prado de Morais; Rafael Nascimento; Luiz Ricardo Goulart; Basuthkar J Rao; Bjarni Asgeirsson; Abhaya M Dandekar
Journal:  F1000Res       Date:  2014-12-05

Review 6.  Risks Posed by Reston, the Forgotten Ebolavirus.

Authors:  Diego Cantoni; Arran Hamlet; Martin Michaelis; Mark N Wass; Jeremy S Rossman
Journal:  mSphere       Date:  2016-12-28       Impact factor: 4.389

7.  Structure and assembly of the Ebola virus nucleocapsid.

Authors:  William Wan; Larissa Kolesnikova; Mairi Clarke; Alexander Koehler; Takeshi Noda; Stephan Becker; John A G Briggs
Journal:  Nature       Date:  2017-11-08       Impact factor: 49.962

8.  Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses.

Authors:  Eric C Dunham; Logan Banadyga; Allison Groseth; Abhilash I Chiramel; Sonja M Best; Hideki Ebihara; Heinz Feldmann; Thomas Hoenen
Journal:  Nat Commun       Date:  2015-08-05       Impact factor: 14.919

9.  Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses.

Authors:  Morena Pappalardo; Miguel Juliá; Mark J Howard; Jeremy S Rossman; Martin Michaelis; Mark N Wass
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

10.  Ebola Virus Infection: Overview and Update on Prevention and Treatment.

Authors:  Miguel J Martínez; Abdulbaset M Salim; Juan C Hurtado; Paul E Kilgore
Journal:  Infect Dis Ther       Date:  2015-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.